Related Experiment Videos
18F-FDG PET/CT in Metastatic Extramammary Paget's Disease
Alex Cheen Hoe Khoo1, Kheng Wei Yeoh2
1From the Departments of Nuclear Medicine.
Abstract:
Extramammary Paget's disease (EMPD) is a rare disease with an estimated prevalence of 0.1 to 2.4 per 1,000,000 person-years. Metastatic EMPD has a poor prognosis with a 5-year survival of approximately 7%. Local therapy is the only curative option with surgery being recommended for resectable disease. It is therefore crucial to be able to stage such patients appropriately. The utility of F-FDG PET/CT for this disease is not well established. We share a case on how F-FDG PET/CT was used to stage metastatic EMPD.
Insights
Extramammary Paget's disease (EMPD) is rare. This case study explores using F-FDG PET/CT for staging metastatic EMPD, which has a poor prognosis and requires accurate staging for curative surgery.
Area of Science:
- Oncology
- Nuclear Medicine
Background:
- Extramammary Paget's disease (EMPD) is a rare malignancy with limited treatment options.
- Metastatic EMPD carries a poor prognosis, emphasizing the need for accurate staging.
- Surgical resection is the primary curative modality for localized disease.
Observation:
- The utility of F-FDG PET/CT in staging EMPD is not well-established.
- This report details a case where F-FDG PET/CT was employed for staging metastatic EMPD.
- The case highlights the potential role of F-FDG PET/CT in managing this rare cancer.
Findings:
- F-FDG PET/CT can provide valuable information for staging metastatic EMPD.
- Accurate staging is critical for determining appropriate treatment strategies.
- The findings suggest F-FDG PET/CT may aid in surgical planning and patient management.
Implications:
- This case contributes to understanding the role of F-FDG PET/CT in EMPD.
- Improved staging accuracy can lead to better patient outcomes.
- Further research is warranted to establish F-FDG PET/CT as a standard tool for EMPD staging.